The prognosis in children with refractory or relapsed (r/r) T-cell acute lymphoblastic leukaemia (T-ALL) or lymphoblastic lymphoma (T-LBL) is poor. Nelarabine (Ara-G) has successfully been used as salvage therapy in these children, but has been associated with significant, even fatal, neurotoxicities. We retrospectively analysed 52 patients with r/r T-ALL/T-LBL aged ≤19 years who were treated with Ara-G alone (n = 25) or in combination with cyclophosphamide and etoposide (n = 27). The majority of patients (45/52) received 1-2 cycles of Ara-G. Seventeen patients (32Á7%) had refractory disease, 28 (53Á8%) were in first relapse and 7 (13Á5%) were in second relapse. A response to Ara-G was achieved in 20 patients and 15 (28Á8%) were in remission at last follow-up. Twelve patients (23Á1%) had neurotoxic adverse effects (neuro-AE) of any grade, of whom 7 (13Á5%) developed neurotoxicity ≥ grade III. The most frequent neuro-AEs were peripheral motor neuropathy (19Á2%), peripheral sensory neuropathy (11Á5%) and seizures (9Á6%). Three patients died of central neuro-AE after 1-2 cycles of combination therapy. Patients with neurotoxicity were significantly older (median 15Á17 years) than those without (10Á34 years, P = 0Á017). No differences were observed between mono-and combination therapy concerning outcome and neuro-AE. The incidence of neuro-AE was not associated with concurrent intrathecal therapy or prior central nervous system irradiation.
Around 80% of children and adolescents with T-lineage acute lymphoblastic leukaemia (T-ALL) and lymphoblastic lymphoma (T-LBL) can be cured by current first-line treatment protocols. (Van Vlierberghe et al, 2008; Schrappe et al, 2011; Bergeron et al, 2015; Patrick & Vora, 2015; Matloub et al, 2016) By contrast, the prognosis in children with refractory or relapsed T-ALL/LBL is very poor. (Einsiedel et al, 2005; Nguyen et al, 2008; Burkhardt et al, 2009; von Stackelberg et al, 2011) Nelarabine (Ara-G), a purine nucleoside analogue, has shown impressive single agent clinical activity in T-cell malignancies and is approved by the European Medicines Academy (EMA) for the treatment of refractory and relapsed T-cell malignancies who failed at least two prior regimens. (Berg et al, 2005; Buie et al, 2007; Cooper, 2007; Cohen et al, 2008; Reilly & Kisor, 2009; Gokbuget et al, 2011) In children, response rates of up to 50% in first bone marrow relapse are reported. (Berg et al, 2005) A combination of Ara-G, etoposide and cyclophosphamide has been used as salvage therapy in children with refractory or relapsed T-cell leukaemia and lymphoma. (Commander et al, 2010) The most common and dose-limiting side effects in phase I/II trials were neurological. (Berg et al, 2005; Kurtzberg et al, 2005; Cohen et al, 2008; Gandhi et al, 2008) In heavily pre-treated patients, Ara-G has been associated with significant neurotoxicities (e.g. GuillainBarre syndrome, depressed level of consciousness, peripheral neuropathy and myelopathy) and even fatal neurological side effects. (Hartz et al, 2013; Ngo et al, 2015) In a single agent phase II study from the Children 0 s Oncology Group (COG) of Ara-G in children and young adults with refractory T-cell malignancies, two dose de-escalations became necessary due to neurotoxicity. (Berg et al, 2005) The most common non-haematological side effects were sensory and motor neuropathy and musculoskeletal pain also for the combination of Ara-G, etoposide and cyclophosphamide. (Commander et al, 2010) Great hopes have been set on the use of Ara-G in the treatment of refractory or relapsed T-cell ALL/LBL. (Gokbuget et al, 2011) However, due to these reports on severe and even fatal neurological side effects, the use of Ara-G in children has remained relatively restricted.
Our study aimed at evaluating neurotoxicity and outcome of heavily pre-treated children with refractory or relapsed T-ALL/-LBL treated with Ara-G or a combination of Ara-G, etoposide and cyclophosphamide on an individual basis.
Patients and Methods

Patients
We retrospectively analysed 52 children and adolescents with relapsed or refractory T-ALL/T-LBL aged ≤19 years of age who were treated with Ara-G alone or Ara-G in combination (details on Ara-G dosage are given in Table SI ) with cyclophosphamide (5 9 440 mg/m 2 ) and etoposide (5 9 100 mg/m 2 ) between 2008 and 2015. All patients were registered in the databases of the Berlin-Frankf€ urt-M€ unster ALL (ALL-BFM),
Co-operative ALL (CoALL) or the BFM relapsed ALL (ALL-REZ BFM) study groups in Germany or Dutch Childhood Oncology Group -Early Clinical Trial Consortium (DCOG-ECTC) in the Netherlands upon informed consent. Patients receiving Ara-G were identified in these databases and by a questionnaire to the participating centres. Data were finalized by an additional questionnaire to the centres that had treated the patients, in which the questions regarding "event" after Ara-G (and further) treatment as well as outcome at the last follow-up were added by the centres. All patients were followed until March 2016 or until death, respectively. Patients who received Ara-G had been refractory to previous chemotherapy or were in cytological remission after therapy according to protocol. Patients in cytological remission were either minimal residual disease (MRD) negative (<10 À4 ), MRD positive (≥10 À4 ) or had no MRD result available.
Statistical analyses
Differences in categorical parameters between groups were calculated with the Chi-square or Fisher's exact test, in continuous parameters using the Mann Whitney-U test. Independency of the influence of single variables on neurotoxicity was tested using the logistic regression analysis. The level of significance was set at P ≤ 0Á05. The severity of neurotoxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (https://evs.nci.nih.gov/ ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7. pdf). Efficacy of treatment was assessed comparing the tumour load before and after Ara-G application. Tumour load was quantified using conventional light microscopy cytology (>=5% of blasts) or using polymerase chain reaction quantification of clonespecific T cell receptor rearrangements or detecting residual leukaemic cells (MRD). (Eckert et al, 2015) Response was defined as a decline of disease burden of at least one log step, stable disease/non-response as disease load remaining in the same log step and progression as increase of disease load of at least one log step. MRD negativity was defined as no detection of a clone-specific signal.
Results
Patient characteristics
Patients were treated between November 2002 and February 2016. Median follow-up was 4 months (range 1-51 haematopoetic stem cell transplantation (HSCT) before Ara-G treatment, 29 patients proceeded to HSCT after Ara-G treatment and 16 patients did not receive HSCT at all. Thirteen patients with primary disease received therapy according to BFM protocols, three were treated according to other protocols (ALL-MB8, CoALL, LAL-SEHOP-PETHEME-2013) and therapy details were not available for one patient. Twenty-one of the 35 relapsed patients received protocol therapy (20 ALL-REZ-BFM; one ALL R3), 11 patients received non-protocol therapy. Three patients received only Ara-G containing chemotherapy as relapse therapy. In addition to the protocol therapy, ten patients received interventional courses that contained liposomal daunorubicin/ fludarabine/cytarabine or a clofarabine-containing combination chemotherapy. Seven patients received other additional chemotherapy and four patients received additional immunotherapy (PD-1-inhibitor plus ex vivo-stimulated Natural Killer (NK) cells; NK cells/interleukin 15 plus human mesenchymal stem cells; OKT3 plus chemotherapy; radioimmunotherapy). About one quarter (14/52, 26Á9%) of the patients had cranial irradiation before Ara-G treatment. Previous neurotoxicity had been described in 15 patients.
Nelarabine treatment and efficacy
One cycle of Ara-G was administered in 22 of the 52 patients, and was as combination therapy in 12 of them. Thirty patients received two or more cycles of Ara-G, 15 of them as combination therapy. Eighteen of the 26 patients (76Á9%) with available data regarding response to Ara-G treatment (cytological or MRD result before and after Ara-G therapy) achieved a response, whereas no response was observed in 8 patients. Two of the 6 patients with isolated extramedullary (IEM) relapse responded to Ara-G treatment, whereas 4 did not. Four of the patients with IEM had T-LBL, of whom three showed progression after nelarabine treatment, one responded to treatment, but suffered a subsequent relapse. Fifteen patients achieved a complete remission. Twenty-two patients suffered a relapse after Ara-G treatment. At the last follow-up, 36 patients had died: three due to Ara-G related toxicity, one related to other treatment, 19 due to relapse, 12 due to non-response/progressive disease and one due to other causes. The median follow-up of the 16 surviving patients was 10 months (1-51 months). There was no correlation of disease status (refractory disease or relapse, P = 0Á30), location of disease (P = 0Á80) or HSCT prior to nelarabine (P = 0Á55) to response.
Nelarabine monotherapy compared to combination therapy
Ara-G monotherapy was administered in 25 of the 52 patients, 27 children and adolescents received combination therapy with cyclophosphamide and etoposide (Table IB and  SI) . In primary refractory disease, 12 of 17 patients (70Á6%) received combination therapy, whereas combination therapy was given only in 15 of 35 relapsed patients (42Á9%). Response rates were similar in patients receiving monotherapy (7/13; 53Á8%) compared to combination therapy (11/13; 84Á6%). Likewise, in patients with isolated extramedullary diseasae no difference in response was observed [1 out of 2 (50%) versus 1 out of 4 (25%)]. Similarly, no difference was observed in the number of patients sustaining neurotoxic side effects (4/25 vs. 8/27). All patients who died of neurotoxicity received combination therapy (Table SII) . Previous to treatment with Ara-G, about half of the patients had suffered from neurotoxic side effects and almost as many patients underwent previous cranial irradiation in both groups.
Nelarabine neurotoxicity
Twelve of the 52 patients (23Á1%) had sustained neurotoxic side effects of any grade, 7 (13Á5%) with neurotoxicity ≥ grade III according to CTCAE 4.03 (https://evs.nci.nih.gov/ ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7. pdf). Six of the 12 patients with neurotoxicity had refractory Ab, antibody; ALL-REZ-BFM protocol, ALL relapse-BFM protocol; BFM protocol, Berlin-Frankf€ urt-M€ unster protocol; BM, bone marrow; BM1, <5% leukaemic blasts in the bone marrow aspirate; BM2, >5 and ≤25% leukaemic blasts in the bone marrow aspirate; BM3, >25% leukaemic blasts in the bone marrow aspirate; CNS, central nervous system; DNX/FLA, daunoxome, fludarabine, high dose-cytarabine; HSCT, allogeneic haematopoetic stem cell transplantation; IEM, isolated extramedullary; MRD, minimal residual disease; NK cells, natural killer cells; T-ALL, T cell acute lymphoblastic leukaemia; T-LBL, T cell lymphoblastic lymphoma; TRD, treatment-related death. Ab, antibody; ALL-REZ-BFM protocol, ALL relapse-BFM protocol; BFM protocol, Berlin-Frankf€ urt-M€ unster protocol; BM, bone marrow; BM1, <5% leukaemic blasts in the bone marrow aspirate; BM2, >5 and ≤25% leukaemic blasts in the bone marrow aspirate; BM3, >25% leukaemic blasts in the bone marrow aspirate; CNS, central nervous system; DNX/FLA, daunoxome, fludarabine, high dose-cytarabine; HSCT, allogeneic haematopoetic stem cell transplantation; IEM, isolated extramedullary; MRD, minimal residual disease; NK cells, natural killer cells; T-ALL, T cell acute lymphoblastic leukaemia; T-LBL, T cell lymphoblastic lymphoma; TRD, treatment-related death.
primary disease, six had relapsed, all of which were very early relapses (1st relapse: n = 4, 2nd relapse: n = 2). Neurotoxicity occurred within/after the first cycle in 9 patients (75% of patients with neurotoxicity) and after the second cycle in 3 patients (25%). In two patients neurotoxicity reoccurred at a higher grade in the subsequent cycle. In most patients it persisted beyond completion of Ara-G infusion. Multiple neurotoxic side effects occurred in individual patients (see Table II for details). Three patients died due to Ara-G related central neurotoxicity, two of them after a single course of Ara-G treatment (Table SII) . These patients also had peripheral neuropathy grade IV. Only two of the 12 patients (16Á7%) survived, both of whom were in complete remission at the last follow-up, one at 5 months and one at 51 months after nelarabine treatment. In univariate analysis, gender (P = 1Á0), location of disease prior to nelarabine treatment (P = 0Á27), additional therapy (P = 0Á57), relapse of disease (P = 0Á25), previous HSCT (P = 0Á55), previous cranial irradiation P = 0Á79), previous neurotoxicity (P = 0Á23), nelarabine as monotherapy or combination therapy (P = 0Á61), number of cycles of nelarabine (P = 0Á66) and response to nelarabine therapy (P = 0Á58) had no influence on neurotoxicity due to nelarabine. However, patients experiencing neurotoxicity were significantly older [15Á17 years (range 4Á50-18Á42 years)] than those who did not [10Á34 years (2Á25-18Á75 years)] (P = 0Á017). Likewise, significantly more patients 10 years of age or older experienced neurotoxicity as compared to the younger cohort (P = 0Á04). It was confirmed in a multivariate logistic regression analysis, that patient age was associated (P = 0Á041) with neurotoxicity, while all other parameters mentioned above did not show any association (P > 0Á05).
Discussion
We analysed neurotoxicity and outcome of nelarabine therapy alone or in combination with cyclophosphamide and etoposide in heavily pre-treated children with refractory or relapsed T-ALL/T-LBL. About one quarter (23%) experienced some type of neurotoxicity, 13% developed ≥ grade 3 neurotoxicity and three of them (25% of patients with neurotoxicity) died due to neurotoxic side effects. In previous studies on Ara-G treatment in children, up to a third of patients developed peripheral sensory and/or motor neuropathy of any severity, and grade 3 or 4 neurotoxicity was the dose-limiting toxicity. (Berg et al, 2005; Kurtzberg et al, 2005; Cohen et al, 2008; DeAngelo, 2009) Addition of Ara-G to either a BFM 86-based chemotherapy regimen (Dunsmore et al, 2012) or to a COG-augmented BFM chemotherapy regimen (Winter et al, 2015) did not lead to significant different incidences of neurotoxicities. This is in line with our findings showing no difference of neurotoxicity between Ara-G monotherapy and combination therapy.
Ara-G-related neurological adverse events could be influenced by previous treatment with neurotoxic drugs, such as vincristine, high-dose cytarabine, high-dose methotrexate, intrathecal chemotherapy and/or cranial irradiation. In our cohort, we could not confirm the relationship between pretreatment and the development of neurotoxicity after Ara-G. However, this might be a result of retrospective data collection.
Severity and time of occurrence of (severe) neurological adverse events differed widely among all regimens reported so far and also within each study cohort. Thus, they might be related to the Ara-G dose administered (28% at a dose level of ≥900 mg/m 2 vs. 17% at doses of ≤650 mg/m 2 ; Berg et al, 2005) as well as cumulative effects in the body. All of the patients in our cohort who died due to Ara-G related neurotoxicity did so after receiving not more than two courses. Moreover, all patients received Ara-G according to the dose recommendation for paediatric patients of 650 mg/m 2 IV for 5 consecutive days (Buie et al, 2007; Dunsmore et al, 2012; Kawakami et al, 2013) or lower. Ara-G-related neurotoxicity has been reported to be gradually reversible, to resolve following completion of Ara-G infusion, and/or to partially recur in subsequent cycles. (Berg et al, 2005; Commander et al, 2010) In our study, occurrence of neurotoxicity varied, arising within/after the first course of Ara-G or after the second course with or without recurrence in subsequent courses. In most patients, neurotoxicity persisted beyond completion of Ara-G infusion independent of the number of cycles, in some of them deteriorating and/or persisting for months. There are consistent reports on some cases, in which central and peripheral neurotoxicities led to fatal outcomes. (Kawakami et al, 2013) These fatal cases cannot be attributed to a particular factor. However, Ara-G treatment prior to human leucocyte antigen-haploidentical stem cell transplantation and the number of doses of intrathecal therapies have been suggested to be associated with neurotoxicity. (Commander et al, 2010; Kawakami et al, 2013) In our analysis, only older age of patients played a role in neurotoxicity, which was identified as a risk factor by univariate and multivariate analysis. All other parameters investigated did not have an influence on neurotoxicity. This is in accordance with previous studies, which could not associate the incidence of neurological events with particular clinical or laboratory features, concurrent intrathecal therapy or prior CNS radiation therapy. (Berg et al, 2005) Neurotoxicity may be associated with abnormal purine metabolism (Stoop et al, 1977; Rijksen et al, 1987) , concurrent medications such as ketamine anaesthesia or selective serotonin reuptake inhibitors. (Dunsmore et al, 2012) Ara-G is eliminated via the kidney, thus, heavily pre-treated patients with decreased renal function might be more susceptible to neurological adverse events due to prolonged exposure to Ara-G. (Buie et al, 2007) Our data were not sufficient to analyse the impact of the Response rates to nelarabine treatment have been comprehensively evaluated in different settings in both children and adults and have been reported to achieve 50-70%. (Berg et al, 2005; Kurtzberg et al, 2005; Cooper, 2007; Gandhi et al, 2008; DeAngelo, 2009; Commander et al, 2010; Gokbuget et al, 2011) In our study, about 50% of patients responded as defined, by a decrease of tumour burden of at least one log step. As our analysis was not compiled to determine the efficacy of a nelarabine-based therapy, data on response were incomplete and, thus, response might be underrated.
Our data identified older age as a risk factor for nelarabine-associated neurotoxicity. Further prospective research is necessary to identify risk factors and causes of nelarabinerelated neurological adverse events. 
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